Eiko Lifesciences Ltd

Eiko Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. The closure will be effective from Wednesday, July 1, 2026, and will remain in effect for 48 hours after the upcoming Board Meeting. This meeting is scheduled to consider, among other items, the Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The exact date of the Board Meeting will be communicated separately. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, to prevent potential insider trading.

Eiko Lifesciences Ltd has re-appointed M/s NP Rajput & Co as its Internal Auditor for the financial year 2026-27. The decision was made during the Board Meeting held on May 26, 2026, following the recommendation of the Audit Committee. This appointment adheres to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Eiko Lifesciences Ltd has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The announcement was made following a Board of Directors meeting held on May 26, 2026. The board also approved the appointment of M/s NP Rajput & Co. as Internal Auditor for the financial year 2026-27. The auditor's report issued by PSV Jain & Associates expressed an unmodified opinion on the financial results.

Eiko Lifesciences Ltd has scheduled a Board of Directors meeting on May 26, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ending March 31, 2026. The trading window for designated persons remains closed from April 1, 2026, until 48 hours after the declaration of the results.

Bhavesh Dhirajlal Tanna, a promoter of Eiko Lifesciences Ltd, has acquired 4,50,000 equity shares and 15,50,000 warrants on a preferential basis. This acquisition represents 3.14% (on non-diluted basis) and 2.60% (on diluted basis) of the issued and subscribed equity shares of Eiko Lifesciences Limited. Post conversion of all warrants, his aggregate holding would be 23,90,000 equity shares, representing 13.82%.

On 24th February 2026, Eiko Lifesciences Ltd's Board of Directors allotted 1,75,000 equity shares and 1,50,000 warrants on a preferential basis to Lenus Finvest Private Limited, a Promoter Group Entity. This acquisition resulted in Lenus Finvest Private Limited holding 1.22% (non-diluted) and 1.09% (diluted) of the issued and subscribed equity shares of Eiko Lifesciences Limited. Post conversion of all warrants, Lenus Finvest Private Limited would hold 15.56% of the company.

Eiko Lifesciences Ltd has allotted 6,25,000 Equity Shares and 29,50,000 Warrants on a preferential basis to various allottees. The Equity Shares are priced at Rs. 55/- per share, including a premium of Rs. 45/-. The Warrants are convertible into 1 (one) Equity Share of the Face Value of Rs. 10/- at a price of Rs. 55/- per equity share, including a premium of Rs. 45/-. The total amount to be received on conversion of Warrants into Equity Shares is Rs. 16,22,50,000. The allottees include Lenus Finvest Private Limited, Bhavesh Dhirajlal Tanna, VSquare Pharmachem Private Limited, Murlidhar Mohanlal Lakhiani HUF, and Amir Hasanali Lalani. These shares will rank pari-passu with the existing equity shares of the Company. The Company has received in-principle approval from the Stock Exchanges for this issue.

Eiko Lifesciences Ltd, a company based in Thane, MH, has approved the unaudited financial results for the quarter and nine months ended 31 December 2025. The results were prepared in accordance with Indian Accounting Standard 34 and other accounting principles generally accepted in India. The company's revenue from operations for the nine months ended 31 December 2025 was INR 2,789.82 lakhs, compared to INR 2,589.79 lakhs for the same period in the previous year. The results were reviewed by the Audit Committee and approved by the Board of Directors on 29 January 2026.

Eiko Lifesciences Ltd has informed the BSE that the company's Board of Directors will meet on 29th January 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ending on 31st December 2025. The Trading Window for dealing in securities of the Company for all Designated Persons has been closed since 1st January 2026 and will remain closed for 48 hours after the declaration of the Unaudited Financial Results.

Eiko Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct. The closure is effective from Thursday, 015t January, 2026 until 48 hours after the Board Meeting where the approval of Un-Audited Standalone and Consolidated Financial Results for the quarter ending 31st December, 2025 will be considered. The date of the Board Meeting will be intimated separately.